Skip to Main Content

Compugen Ltd

CGEN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
CGEN Income Statement
CGEN Balance Sheet
CGEN Cash Flow

Recent trades of CGEN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CGEN Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CGEN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CGEN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by CGEN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Triple combination antibody therapies Nov. 26, 2024
  • Patent Title: Anti-pvrig antibodies and methods of use Oct. 24, 2023
  • Patent Title: Pvrig polypeptides and methods of treatment Oct. 24, 2023
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Jul. 18, 2023
  • Patent Title: Anti-pvrig antibodies and methods of use Apr. 11, 2023
  • Patent Title: Triple combination antibody therapies Jan. 18, 2022
  • Patent Title: Anti-pvrig antibodies and methods of use Jan. 11, 2022
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Aug. 25, 2020
  • Patent Title: Pvrig polypeptides and methods of treatment Feb. 04, 2020
  • Patent Title: Anti-pvrig antibodies and methods of use Jul. 16, 2019
  • Patent Title: Anti-pvrig antibodies and methods of use Mar. 12, 2019
  • Patent Title: Anti-tigit anibodies, anti-pvrig antibodies and combinations thereof Feb. 26, 2019
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Nov. 13, 2018
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Oct. 16, 2018
  • Patent Title: Anti-pvrig antibodies and methods of use Jul. 25, 2017
  • Patent Title: C10rf32 antibodies, and uses thereof for treatment of cancer Apr. 11, 2017
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jan. 31, 2017
  • Patent Title: Heparanase splice variant Aug. 30, 2016
  • Patent Title: Polypeptides and uses thereof for treatment of autoimmune disorders and infection Aug. 30, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer Aug. 09, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jun. 28, 2016
  • Patent Title: Soluble vegfr-1 variants for diagnosis of preeclampsia May. 24, 2016
  • Patent Title: Angiopoietin derived peptides Feb. 09, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Aug. 18, 2015
  • Patent Title: Compositions and methods for treatment of drug resistant multiple myeloma Apr. 07, 2015
  • Patent Title: Bioactive peptides and methods of using same Mar. 24, 2015
  • Patent Title: Method of treating an ischemia-reperfusion injury-related disorder by administering gpcr ligands Sep. 09, 2014
  • Patent Title: Clusterin derived peptide Nov. 05, 2013
  • Patent Title: Angiopoietin derived peptides Sep. 10, 2013
  • Patent Title: Gp96 derived peptides Aug. 20, 2013
  • Patent Title: Bioactive peptides and methods of using same Jul. 23, 2013
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Apr. 09, 2013
  • Patent Title: Peptide ligands for g-protein coupled receptors Jan. 08, 2013
  • Patent Title: Polynucleotides encoding polypeptides and methods using same May. 10, 2011
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer Mar. 15, 2011
  • Patent Title: Peptides which bind to g protein-coupled receptors Feb. 08, 2011
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis Nov. 30, 2010
  • Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Jul. 20, 2010
  • Patent Title: Human thrombospondin polypeptide Jun. 29, 2010
  • Patent Title: Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof Jun. 22, 2010
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease May. 11, 2010
  • Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Mar. 16, 2010
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Feb. 23, 2010
  • Patent Title: Variants of human glycoprotein hormone alpha chain: compositions and uses thereof Feb. 02, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CGEN in WallStreetBets Daily Discussion

CGEN News

Recent insights relating to CGEN

CNBC Recommendations

Recent picks made for CGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CGEN

CGEN Top Shareholders
Shareholder
Shares Held
CGEN Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CGEN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CGEN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top